NCT05751720View on ClinicalTrials.gov

Effect on Non-Alcoholic Fatty Liver Disease in Patients With Type 2 Diabetes Mellitus With Gastric Inhibitory Polypeptide/Glucagon Like Peptide-1 Analogue

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

October 1, 2023

Primary Completion Date

October 31, 2024

Study Completion Date

February 28, 2025

Conditions
Non-Alcoholic Fatty Liver DiseaseNon-alcoholic SteatohepatitisType 2 DiabetesLiver Fat
Interventions
DRUG

GIP/GLP-1a

The group will receive GLP-1 analogues (subcutaneous Tirzepatide). The dose of Tirzepatide is 0.25 mg once weekly for 4 weeks then 0.5 mg once weekly.

Trial Locations (1)

15551

RECRUITING

Internal Medicine, College of Medicine and Health Sciences, Al Ain City

All Listed Sponsors
lead

Dr Adnan Agha

OTHER